Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | XDH | P47989 | 4/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19478329 | 0.89 | BACE1 (0.36) | KIF11BACE1MTTPDHODHPARP1 | |
| SCHEMBL16570944 | 0.87 | SLC22A12 (0.39) | XDHSLC22A12KDM1A | |
| SCHEMBL19478304 | 0.86 | SCN9A (0.40) | PTGDR2XDHSLC22A12 | |
| SCHEMBL16580114 | 0.86 | GRM2 (0.44) | XDHSLC22A12KDM1A | |
| SCHEMBL16580059 | 0.86 | NTRK1 (0.48) | XDHSLC22A12KDM1ACNR1 | |
| SCHEMBL19457992 | 0.85 | CCNC (0.44) | XDHSLC22A12 | |
| SCHEMBL16580108 | 0.85 | SLC22A12 (0.39) | XDHSLC22A12KDM1ACNR1 | |
| SCHEMBL16580111 | 0.84 | SLC22A12 (0.38) | PTGDR2XDHSLC22A12KDM1APARP1 | |
| SCHEMBL16580115 | 0.83 | SLC22A12 (0.37) | XDHSLC22A12KDM1A | |
| SCHEMBL16580116 | 0.83 | MCL1 (0.43) | XDHSLC22A12PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | claimed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | claimed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | DRD2, HCRTR1, CDR2 | PTGDR2 1021/4885XDH 1297/4885SLC22A12 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.